NEXENTIS TECHNOLOGIES INC. Unrealized Gain (Loss) on Investments
NEXENTIS TECHNOLOGIES INC. (NXTS) reported Unrealized Gain (Loss) on Investments of $662.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:UnrealizedGainLossOnInvestments · last filed 2026-08-13
- NEXENTIS TECHNOLOGIES INC. unrealized gain (loss) on investments for the quarter ending 2026-06-30 was $662.00K.
- NEXENTIS TECHNOLOGIES INC. unrealized gain (loss) on investments for the quarter ending 2024-12-31 was $442.16K, a 29.41% decline year-over-year.
- NEXENTIS TECHNOLOGIES INC. unrealized gain (loss) on investments for the quarter ending 2024-09-30 was $970.50K.
- NEXENTIS TECHNOLOGIES INC. unrealized gain (loss) on investments for the quarter ending 2024-06-30 was $130.37K, a 27.68% increase year-over-year.
- NEXENTIS TECHNOLOGIES INC. unrealized gain (loss) on investments for fiscal 2024 was $1.30M.
| Period end | Unrealized Gain (Loss) on Investments 3 month | Unrealized Gain (Loss) on Investments 6 month | Unrealized Gain (Loss) on Investments 9 month | Unrealized Gain (Loss) on Investments 9 month as first filed | Unrealized Gain (Loss) on Investments 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $662.00K 10-Q · filed 2026-08-13 | $199.00K 10-Q · filed 2026-08-13 | |||
| 2024-12-31 | $442.16K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $1.41M derived: sum of 2 quarters · filed 2025-03-31 | $1.54M derived: sum of 3 quarters · filed 2025-03-31 | $1.30M 10-K · filed 2025-03-31 | |
| 2024-09-30 | $970.50K 10-Q · filed 2024-11-14 | $1.10M derived: sum of 2 quarters · filed 2024-11-14 | $856.84K 10-Q · filed 2024-11-14 | $1.81M derived: sum of 4 quarters · filed 2025-03-31 | |
| 2024-06-30 | $130.37K 10-Q · filed 2024-08-14 | $46.42K 10-Q · filed 2024-08-14 | $840.74K derived: sum of 3 quarters · filed 2025-03-31 | $826.20K derived: sum of 4 quarters · filed 2025-03-31 | |
| 2024-03-31 | $83.94K 10-Q · filed 2024-05-15 | $710.37K derived: sum of 2 quarters · filed 2025-03-31 | $695.84K derived: sum of 3 quarters · filed 2025-03-31 | $797.94K derived: sum of 4 quarters · filed 2025-03-31 | |
| 2023-12-31 | $626.42K derived: 10-K 9 month − 10-Q 6 month · filed 2025-03-31 | $611.89K derived: sum of 2 quarters · filed 2025-03-31 | $714.00K 10-K · filed 2025-03-31 | $713.59K 10-K · filed 2024-04-01 | |
| 2023-09-30 | -$14.53K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-11-14 | $87.58K 10-Q · filed 2023-11-14 | |||
| 2023-06-30 | $102.11K 10-Q · filed 2023-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |